expected survival if not receiving treatment inhibitor includes but is not limited to any suitable molecule compound protein or fragment thereof nucleic acid formulation or substance that can regulate nos activity in such a way that nos is decreased the inhibitor can include but is not limited to the specifically identified compounds vii and x alkyl refers to saturated aliphatic groups including straight chain branched chain and cyclic groups having the number of carbon atoms specified or if no number is specified having up to 12 carbon atoms the term u201c cycloalkyl u201d as used herein refers to a mono bi or tricyclic aliphatic ring having 3 to 14 carbon atoms and preferably 3 to 7 carbon atoms aryl refers to and which is included with the term u201c carbocyclic ring structure u201d refers to an unsubstituted or substituted aromatic ring substituted with one two or three substituents selected from lower alkoxy lower alkyl lower alkylamino hydroxy halogen cyano hydroxyl mercapto nitro thioalkoxy carboxaldehyde carboxyl carboalkoxy and carboxamide including but not limited to carbocyclic aryl heterocyclic aryl and biaryl groups and the like all of which may be optionally substituted preferred aryl groups include phenyl halophenyl loweralkylphenyl napthyl biphenyl phenanthrenyl and naphthacenyl as used herein the term u201c heterocyclic ring u201d or u201c heterocyclic ring system u201d is intended to mean a substituted or unsubstituted member selected from the group consisting of stable monocyclic ring having from 5 7 members in the ring itself and having from 1 to 4 hetero ring atoms selected from the group consisting of n o and s a stable bicyclic ring structure having a total of from 7 to 12 atoms in the two rings wherein.